Tricision advances survivin-targeted DC therapy into Phase 2 glioblastoma trial
The Beijing sponsor moves its second survivin-targeted dendritic cell trial into Phase 2, testing overall survival in newly diagnosed glioblastoma against a field with no approved biomarker-selected cell therapy.
Executive Summary
- Beijing Tricision Biotherapeutics registered a Phase 2 study of its survivin-targeted dendritic cell injection as a first-line addition to surgery and chemoradiotherapy in newly diagnosed glioblastoma, with overall survival as the primary measure.
- The trial follows the sponsor's own earlier-stage study of the same therapy in glioblastoma, giving this expansion an internal track record rather than a first attempt at the biology.
- Survivin-targeted cell therapy remains rare in glioblastoma, and the trial sits in a field with several validated non-cellular options in later lines but no approved biomarker-selected cellular therapy in the newly diagnosed setting.
- The study has not yet begun recruiting, so the near-term signal is enrollment and operational execution rather than clinical data.
The trial
The study, filed under NCT07715097, will enroll an anticipated 30 patients with newly diagnosed, WHO grade 4 glioblastoma who test positive for survivin expression by immunohistochemistry and have undergone tumor resection meeting RANO grade 1 or 2 criteria. Patients receive the dendritic cell injection alongside standard radiotherapy and temozolomide, with no other glioblastoma-directed therapy permitted during the trial. The primary endpoint is overall survival, measured from surgery until death from any cause over up to 36 months, with progression-free survival tracked as a secondary measure. The trial is listed as not yet recruiting, with a start date of September 30, 2026, and a primary completion date of September 30, 2028. NCT07715097Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed GlioblastomaNCT07715097
Sponsor precedent
This is Tricision's second survivin-targeted dendritic cell trial in glioblastoma. The company's earlier Phase 1 study of the same therapy, NCT06524063, established the mechanism in this indication before this Phase 2 registration. The sponsor's active pipeline consists of two trials, both not yet recruiting, indicating this program is its most advanced clinical effort. Moving to a 30-patient, survival-powered Phase 2 without a randomized comparator arm reflects an early efficacy-signal design rather than a registrational study; the trial is not listed as registrational. NCT07715097Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed GlioblastomaNCT07715097
Competitive position
Survivin-directed therapy is sparsely represented in glioblastoma. Among industry trials pairing the target with this indication, one other program, Tricision's own Phase 1 study, has reached clinical testing, and no other sponsor's survivin-targeted asset has advanced past Phase 1 in this disease. The closest comparator outside glioblastoma is Astellas Pharma's sepantronium bromide, a small-molecule survivin inhibitor tested in breast cancer, while the nearest same-modality precedent in glioblastoma is Diakonos Oncology's DOC1021, a dendritic cell immunotherapy directed at a different target. The broader glioblastoma field includes later-line and device-based options such as NovoCure's Optune and GT Medical Technologies' GammaTile, both in Phase 3 testing, but none is a biomarker-selected cellular therapy in the newly diagnosed, first-line setting this trial targets. NCT07715097Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed GlioblastomaNCT07715097
What's ahead
With enrollment not yet open, the near-term signal is whether the trial begins recruiting on its stated September 2026 start date and whether it reaches its 30-patient target within the timelines typical for Phase 2 glioblastoma studies, where comparable trials show a median enrollment period of 830 days. No results, comparator data, or regulatory designation currently attach to the program. NCT07715097Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed GlioblastomaNCT07715097
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.